Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. on October 11, 2024, covering events reported as of October 9, 2024. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Boston, MA. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "ALLR".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary event reported is the resolution of a Nasdaq listing deficiency. Previously, on June 18, 2024, the Company received notice that its common stock failed to maintain the minimum $1.00 closing bid price required by Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. On October 9, 2024, Nasdaq confirmed that the Company's stock maintained a closing bid price of $1.00 or greater for the 20 consecutive business days between September 11, 2024, and October 9, 2024. Consequently, the Company has regained compliance, and the matter is closed.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or new risk factors. The Company issued a press release on October 10, 2024, announcing its regained compliance, which is filed as Exhibit 99.1. The immediate risk of delisting due to the bid price rule has been mitigated by this compliance.
Key Facts for Investor Verification
- Verify the current trading price of ALLR to ensure it remains above the $1.00 threshold to avoid future non-compliance notices.
- Review the press release filed as Exhibit 99.1 for any additional context regarding the stock price recovery.
- Confirm that no other Nasdaq listing deficiencies (e.g., market value of listed securities, shareholder equity) are currently outstanding.